164 related articles for article (PubMed ID: 17671332)
21. Quantification of Vaporised Targeted Nanodroplets Using High-Frame-Rate Ultrasound and Optics.
Zhang G; Lin S; Leow CH; Pang KT; Hernández-Gil J; Long NJ; Eckersley R; Matsunaga T; Tang MX
Ultrasound Med Biol; 2019 May; 45(5):1131-1142. PubMed ID: 30827708
[TBL] [Abstract][Full Text] [Related]
22. A new application of plant virus nanoparticles as drug delivery in breast cancer.
Esfandiari N; Arzanani MK; Soleimani M; Kohi-Habibi M; Svendsen WE
Tumour Biol; 2016 Jan; 37(1):1229-36. PubMed ID: 26286831
[TBL] [Abstract][Full Text] [Related]
23. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy.
Rapoport N; Gao Z; Kennedy A
J Natl Cancer Inst; 2007 Jul; 99(14):1095-106. PubMed ID: 17623798
[TBL] [Abstract][Full Text] [Related]
24. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells.
Wartlick H; Michaelis K; Balthasar S; Strebhardt K; Kreuter J; Langer K
J Drug Target; 2004; 12(7):461-71. PubMed ID: 15621671
[TBL] [Abstract][Full Text] [Related]
25. Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level.
Barrajón-Catalán E; Menéndez-Gutiérrez MP; Falco A; Carrato A; Saceda M; Micol V
Cancer Lett; 2010 Apr; 290(2):192-203. PubMed ID: 19896266
[TBL] [Abstract][Full Text] [Related]
26. Nanoparticles as image enhancing agents for ultrasonography.
Liu J; Levine AL; Mattoon JS; Yamaguchi M; Lee RJ; Pan X; Rosol TJ
Phys Med Biol; 2006 May; 51(9):2179-89. PubMed ID: 16625034
[TBL] [Abstract][Full Text] [Related]
27. Production and characterization of a novel long-acting Herceptin-targeted nanobubble contrast agent specific for Her-2-positive breast cancers.
Jiang Q; Hao S; Xiao X; Yao J; Ou B; Zhao Z; Liu F; Pan X; Luo B; Zhi H
Breast Cancer; 2016 May; 23(3):445-55. PubMed ID: 25691133
[TBL] [Abstract][Full Text] [Related]
28. A nanoparticle for tumor targeted delivery of oligomers.
Liu X; Wang Y; Hnatowich DJ
Methods Mol Biol; 2011; 764():91-105. PubMed ID: 21748635
[TBL] [Abstract][Full Text] [Related]
29. Anti-HER2 VHH Targeted Fluorescent Liposome as Bimodal Nanoparticle for Drug Delivery and Optical Imaging.
Khaleghi S; Rahbarizadeh F; Nikkhoi SK
Recent Pat Anticancer Drug Discov; 2021; 16(4):552-562. PubMed ID: 34365930
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.
Steinhauser I; Spänkuch B; Strebhardt K; Langer K
Biomaterials; 2006 Oct; 27(28):4975-83. PubMed ID: 16757022
[TBL] [Abstract][Full Text] [Related]
31. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
32. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
[TBL] [Abstract][Full Text] [Related]
33. Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging.
Kanazaki K; Sano K; Makino A; Shimizu Y; Yamauchi F; Ogawa S; Ding N; Yano T; Temma T; Ono M; Saji H
Nanomedicine; 2015 Nov; 11(8):2051-60. PubMed ID: 26238078
[TBL] [Abstract][Full Text] [Related]
34. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
35. Characterization of digital waveforms using thermodynamic analogs: detection of contrast-targeted tissue in vivo.
Hughes MS; Marsh JN; Zhang H; Woodson AK; Allen JS; Lacy EK; Carradine C; Lanza GM; Wickline SA
IEEE Trans Ultrason Ferroelectr Freq Control; 2006 Sep; 53(9):1609-16. PubMed ID: 16964911
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption.
Kinoshita M; McDannold N; Jolesz FA; Hynynen K
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11719-23. PubMed ID: 16868082
[TBL] [Abstract][Full Text] [Related]
37. Spectral Photon-Counting Molecular Imaging for Quantification of Monoclonal Antibody-Conjugated Gold Nanoparticles Targeted to Lymphoma and Breast Cancer: An
Moghiseh M; Lowe C; Lewis JG; Kumar D; Butler A; Anderson N; Raja A
Contrast Media Mol Imaging; 2018; 2018():2136840. PubMed ID: 30662379
[TBL] [Abstract][Full Text] [Related]
38. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine.
Chiu SJ; Ueno NT; Lee RJ
J Control Release; 2004 Jun; 97(2):357-69. PubMed ID: 15196762
[TBL] [Abstract][Full Text] [Related]
39. Novel dual-mode nanobubbles as potential targeted contrast agents for female tumors exploration.
Yang H; Zhou T; Cai W; Yi X; Liu X; Wang Y; Zhang L; Duan Y
Tumour Biol; 2016 Oct; 37(10):14153-14163. PubMed ID: 27539728
[TBL] [Abstract][Full Text] [Related]
40. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study.
Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F
J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
